Evidence map›Paper›PMID 36937415›Full record

SynthesisFrontiers in oncology2023

Survival rate of colorectal cancer in China: A systematic review and meta-analysis.

Ren Wang, Jie Lian, Xin Wang, Xiangyi Pang, Benjie Xu, Shuli Tang, Jiayue Shao, Haibo Lu

Full text readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ren WangDepartment of Outpatient Chemotherapy, Harbin Medical University Cancer Hospital, Harbin, China.
Jie LianDepartment of Outpatient Chemotherapy, Harbin Medical University Cancer Hospital, Harbin, China.
Xin WangDepartment of Outpatient Chemotherapy, Harbin Medical University Cancer Hospital, Harbin, China.
Xiangyi PangDepartment of Outpatient Chemotherapy, Harbin Medical University Cancer Hospital, Harbin, China.
Benjie XuDepartment of Outpatient Chemotherapy, Harbin Medical University Cancer Hospital, Harbin, China.
Shuli TangDepartment of Outpatient Chemotherapy, Harbin Medical University Cancer Hospital, Harbin, China.
Jiayue ShaoDepartment of Outpatient Chemotherapy, Harbin Medical University Cancer Hospital, Harbin, China.
Haibo LuDepartment of Outpatient Chemotherapy, Harbin Medical University Cancer Hospital, Harbin, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: This study aims to comprehensively summarize the colorectal survival rate in China. Method: In PubMed and Web of Science, keywords such as "colorectal cancer", "survival" and "China" were used to search literatures in the past 10 years. Random effect models were selected to summarize 1-year, 3-year, and 5-year survival rates, and meta-regression and subgroup analyses were performed on the included studies. Results: A total of 16 retrospective and prospective studies providing survival rates for colorectal cancer in China were included. The 1-year, 3-year, and 5-year survival rates of colorectal cancer in China were 0.79, 0.72 and 0.62, respectively. In the included studies, the 5-year survival rates of stage I (5474 cases), stage II (9215 cases), stage III (8048 cases), and stage IV (4199 cases) colorectal cancer patients were 0.85, 0.81, 0.57 and 0.30, respectively. Among them, the 5-year survival rates of colorectal cancer were 0.82, 0.76, 0.71, 0.67, 0.66, 0.65 and 0.63 in Tianjin, Beijing, Guangdong, Shandong, Liaoning, Zhejiang and Shanghai, respectively. Conclusion: The 5-year survival rate in China is close to that of most European countries, but still lower than Japan and South Korea, and the gap is gradually narrowing. Region, stage, differentiation, pathological type, and surgical approach can affect 5-year survival in colorectal cancer. Systematic review registration: https://www.crd.york.ac.uk/prospero/ identifier, CRD42022357789.

Indexed as

Chinacolorectal cancerepidemiologymeta-analysisoverall survival

Identifiers

PMID36937415
PMCPMC10020492

What Socratic holds

Textfull text, public
LicenceCC BY
measurements read47
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.